Cargando…
Evaluating treatments in rare indications warrants a Bayesian approach
Evaluating efficacy and real-world effectiveness for novel therapies targeting rare mutations or patient subpopulations with unmet needs is a growing challenge in health economics and outcomes research (HEOR). In these settings it may be difficult to recruit enough patients to run adequately powered...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547867/ https://www.ncbi.nlm.nih.gov/pubmed/37799966 http://dx.doi.org/10.3389/fphar.2023.1249611 |